AlphaMadera's AlphaVal page computes The Procter & Gamble Company's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag PG as undervalued, fairly valued, or overvalued.

What is The Procter & Gamble Company's fair value?

Fair value for PG is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value PG?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from PG's most recent reported fundamentals.

PG - The Procter & Gamble Company

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $159.00 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Overvalued Mild

Trading 8.2% above fair value

Current Price $147.04

Bear Case $111.89 23.9% downside ($111.89 - $147.04) / $147.04 = -23.9% $7.26 × 14x P/E

Fair Value $135.87 7.6% downside ($135.87 - $147.04) / $147.04 = -7.6% $7.26 × 17x P/E

Bull Case $159.84 8.7% upside ($159.84 - $147.04) / $147.04 = 8.7% $7.26 × 20x P/E

Adjust Assumptions

P/E Multiple

17.0x

Adjusted EPS

7.26$

Key Value Driver

Normalized P/E multiple (17x base case)

Implied Market Multiple 20.3x

Plain-Language Summary

Our base-case estimate uses a valuation based on adjusted earnings per share and a normalized price-to-earnings multiple. We then blend that result with the average analyst price target of $159.00 from 52 analysts, using a 35% weight on analyst consensus. That produces an estimated intrinsic value of $135.87 per share.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples